Abstract：Objective To summarize the outcome of nasopharyngeal carcinoma (NPC) treated by helical tomotherapy in the Chinese PLA general hospital. Methods Between September 2007 and August 2010, 121 newly diagnosed NPC patients were treated by radiotherapy with Tomotherapy system, with (n=90) or without (n=31) concurrent chemotherapy or molecular target therapy. The prescription dose was 70－74 Gy/33f to primary tumor and positive lymph node planning target volume,60.0－62.7 Gy/33f to high risk planning target volume, and 52－56 Gy/33f to low risk planning target volume. Acute side-effects were evaluated with RTOG/EORTC criteria. Results The remission rate of primary lesion and positive lymph nodes was 95.0% and 99.0%, respectively. The follow-up rate was 100%.The number of patients with 1, 2 and 3 years followed-up were 99, 49, and 7. The 1-, 2-and 3-year local relapse-free survival rates were 97.3%, 97.3% and 97.3%, respectively. The 1-,2-and 3-year nodal relapse-free survival rates were 100%, 100% and 100%,respectively. The 1-,2-and 3-year distant metastasis-free survival rates were 98.4%, 96.3% and 96.3%,respectively. The 1-, 2-and 3-year overall survival rates were 96.5%, 92.6% and 86.8%, respectively. Acute toxicities of skin, oral mucosa and xerostomia with grade 0,1,2 and 3 were 5.0%, 74.4%, 15.7% and 4.9%;0.8%, 37.2%, 57.9% and 4.1%;3.3%, 53.7%,43.0% and 0%, respectively. Xerostomia restored with time, no grade 2 or more xerostomia was observed 1 year after radiation therapy. Concurrent chemotherapy significantly increased incidence of mucositis, esophagitis and tracheitis. Conclusion Helical tomotherapy is efficient, secure and effective modality for the treatment of nasopharyngeal carcinoma.
. Clinic results of 121 nasopharyngeal carcinoma patients treated by helical tomotherapy[J]. Chinese Journal of Radiation Oncology, 2012, 21(2): 97-100.
[1] Mackie TR, Holmes T, Swerdloff S, et al. Tomotherapy:a new concept for the delivery of dynamic conformal radiotherapy. Med Phys,1993,20:1709-1719. [2] Ren G, Du L, Ma L, et al. Clinical observation of 73 nasopharyngeal carcinoma patients treated by helical tomotherapy:the China experience. Technol Cancer Res Treat,2011,10:259-266. [3] Lee N, Xia P, Quivey JM, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma:an update of the UCSF experience. Int J Radiat Oncol Biol Phys,2002,53:12-22. [4] 崔迪,戴相昆,马林,等.鼻咽癌螺旋断层放疗与常规加速器调强放疗的剂量学比较.中华放射肿瘤学杂志,2008,17:169-173. [5] 中国鼻咽癌临床分期工作委员会.2010鼻咽癌调强靶区及剂量设计指引专家共识.中华放射肿瘤学杂志,2011,20:267-269. [6] Baujat B, Audry H, Bourhis J, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma:an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys,2006,64:47-56. [7] Lee AW, Tung SY, Chan AT, et al. Preliminary results of a randomized study (NPC-9902 trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys,2006,66:142-151. [8] Lee AW, Lau WH, Tung SY, et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma:NPC-9901 trial by the Hong Kong nasopharyngeal cancer study group. J Clin Oncol,2005,23:6966-6975. [9] Chan AT, Teo PM, Ngan RK, et al. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma:progression-free survival analysis of a phase Ⅲ randomized trial. J Clin Oncol,2002,20:2038-2044. [10] Yi JL, Gao L, Xu GZ, et al. Treatment results of intensity-modulated radiotherapy for nasopharyngeal carcinoma:an analysis of 147 patients. Chin J Radiat Oncol,2008,17:329-334. [11] Tham IW, Hee SW, Yeo RM, et al. Treatment of nasopharyngeal carcinoma using intensity-modulated radiotherapy-the national cancer centre Singapore experience. Int J Radiat Oncol Biol Phys,2011,75:1481-1486. [12] Lee N, Harris J, Adam S, et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma:radiation therapy oncology group phase Ⅱ trial 0225. J Clin Oncol,2009,27:3684-3690. [13] Zhao Y, Xiao WW, Han F, et al. Long-term outcome and prognostic factors of patients with nasopharyngeal carcinoma treated with intensity-modulated radiation therapy. Chin J Radiat Oncol,2010,19:191-196. [14] Ng WT, Lee MC, Hung WM, et al. Clinical outcomes and patterns of failure after intensity-modulated radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys,2011,79:420-428. [15] Kodaira T, Tomita N, Tachibana H, et al. Aichi cancer center initial experience of intensity modulated radiation therapy for nasopharyngeal cancer using helical tomotherapy. Int J Radiat Oncol Biol Phys,2009,73:1129-1134. [16] Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med,2006,354:567-578. [17] Chan TC, Hsu MM, Boon C, et al. Multicenter, Phase Ⅱ study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol,2005,23:3568-3576.
2012, Vol. 21 
